home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
The Arsenal Files 6
/
The Arsenal Files 6 (Arsenal Computer).ISO
/
health
/
med9605d.zip
/
M9651043.TXT
< prev
next >
Wrap
Text File
|
1996-03-30
|
3KB
|
43 lines
Document 1043
DOCN M9651043
TI Potent inhibition of human immunodeficiency virus by MDL 101028, a novel
sulphonic acid polymer.
DT 9505
AU Taylor DL; Brennan TM; Bridges CG; Mullins MJ; Tyms AS; Jackson R;
Cardin AD; MRC Collaborative Centre, Mill Hill, London.
SO Antiviral Res. 1995 Oct;28(2):159-73. Unique Identifier : AIDSLINE
MED/96126408
AB MDL 101028, a novel biphenyl disulphonic acid urea co-polymer was
designed and synthesised as a heparin mimetic. This low molecular weight
polymer showed potent inhibition of human immunodeficiency virus type 1
(HIV-1) replication in a number of host-cell/virus systems, including
primary clinical isolates of the virus cultured in human peripheral
blood mononuclear cells (PBMCs). When compared with the heterogeneous
polysulphated molecules, heparin and dextran sulphate, this chemically
defined compound showed equivalent antiviral activity with 50%
inhibitory concentrations (IC50s) in the range 0.27-3.0 micrograms/ml in
the host-cell/virus systems tested. MDL 101028 also inhibited the
replication of HIV type 2 and the simian immunodeficiency virus (SIV),
as well as HIV-1 variants resistant to reverse transcriptase inhibitors.
Virus growth was blocked when exposure of T-lymphocytes to MDL 101028
was restricted to the virus absorption stage, or even in whole blood
conditions. MDL 101028 did not irreversibly inactivate virions, and in
contrast to heparin, did not inhibit the attachment of radiolabelled
HIV-1 to CD4+ T-cells. MDL 101028 blocked HIV-induced cell-to-cell
fusion and this activity appears to explain the mechanism of its
antiviral action. The antiviral evaluation of discrete oligomer
molecules of MDL 101028 showed that a polymer chain length of six
repeating units had optimal potency. The lack of anticoagulant
properties and significant antiviral activity in whole blood may allow
the development of MDL 101028 as a treatment of HIV infections.
DE Animal Antiviral Agents/*PHARMACOLOGY Biphenyl
Compounds/*PHARMACOLOGY/TOXICITY Cell Line
Cytotoxins/PHARMACOLOGY/TOXICITY Human HIV-1/*DRUG EFFECTS/METABOLISM
HIV-2/DRUG EFFECTS Polymers/*PHARMACOLOGY Structure-Activity
Relationship Sulfonic Acids/*PHARMACOLOGY SIV/DRUG EFFECTS JOURNAL
ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).